Ignite Creation Date:
2024-05-05 @ 12:10 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00267748
Status:
COMPLETED
Last Update Posted:
2011-09-05
First Post:
2005-12-20
Brief Title:
Sunitinib Malate Schedule 42 vs Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer RCC
Sponsor:
Organization:
Pfizer